Participation trends in 100 m (161 km) ultramarathon running competitions in North America were examined from race results from 1977 through 2008. A total of 32, 352 finishes accounted for by 9815 unique individuals were identified. The annual number of races and number of finishes increased exponentially over the study period. This growth in number of finishes occurred through a combination of (1) an increase in participation among runners >40 years of age from less than 40% of the finishes prior to the mid-1980s to 65-70% of the finishes since 1996, (2) a growth (p < 0.0001) in participation among women from virtually none in the late 1970s to nearly 20% since 2004, and (3) an increase in the average annual number of races completed by each individual to 1.3. While there has been considerable growth in participation, the 161 km ultramarathon continues to attract a relatively small number of participants compared with running races of shorter distances.

Purpose: Despite increased 161-km ultramarathon participation in recent years, little is known about those who pursue such an activity. This study surveyed entrants in two of the largest 161-km trail ultramarathon runs in North America to explore demographic characteristics and issues that affected race performance.Methods: All entries of the 2009 Western States Endurance Run and the Vermont 100 Endurance Race were invited to complete a postrace questionnaire.Results: There were 500 respondents among the 701 race entries (71.3% response). Finish time was found to have a significant (P <.01) negative association with training volume and was generally directly associated with body mass index. Among nonfinishers, the primary reason for dropping out was nausea and/or vomiting (23.0%). Finishers compared with nonfinishers were more likely (P <.02) to report blisters (40.1% vs 17.3%), muscle pain (36.5% vs 20.1%), and exhaustion (23.1% vs 13.7%) as adversely affecting race performance, but nausea and/or vomiting was similar between groups (36.8% vs 39.6%). Nausea and/or vomiting was no more common among those using nonsteroidal anti-infammatory drugs (NS AIDs), those participating in the event with higher ambient temperatures, those with a lower training volume, or those with less experience at finishing 161-km races. Overall use of NSAIDs was high, and greater (P = .006) among finishers (60.5%) than nonfinishers (46.4%).Conclusions: From this study, we conclude that primary performance-limiting issues in 161 -km ultramarathons include nausea and/or vomiting, blisters, and muscle pain, and there is a disturbingly high use of NSAIDs in these events.

S, ANOVA, and t-tests were used to examine participation and performance trends. Results: The mean age of participants increased (P < 0.001) to around 45 yr, with men being an average of 3 yr older (P < 0.001) than women. The increase in average age of starters was accounted for by the growth in participation among women ≥40 yr and men ≥50 yr, and by the decreasing participation among men <50 yr. Between 1986 and 2007, there was an increasing participation among women to around 20% of all starters. With this came improved (P < 0.01) finish times for the top 5 overall women and the top 5 women in the 30-39 and 40-49 yr age groups, whereas performances among the men did not improve over this time span. Average ages of the top performers increased (P ≤ 0.002) since 1990 to the upper 30s for both sexes, but the fastest times among men were comparable across the 30-39 and 40-49 yr age groups. Conclusions: Participation in the WSER has increased among women and older athletes, and the ages of the fastest runners at the WSER have gradually risen to the extent that these runners are older than the ages at which the fastest marathons are run. In contrast to what has been observed for men, finish times have improved for the top women across the last two decades at the WSER....

Background—: Running an ultramarathon has been shown to have a transient negative effect on right ventricular (RV) and left ventricular (LV) function. Additionally, recent findings suggested that ultraendurance athletes may be more at risk of developing a RV cardiomyopathy. The standard echocardiographic assessment of RV function is problematic; however, the introduction of ultrasonic speckle tracking technology has the potential to yield a comprehensive evaluation of RV longitudinal function, providing new insights into this phenomenon. Thus, the primary aim of this exploratory study was to evaluate comprehensively RV structure and function after a 161-km ultramarathon and establish whether changes in the RV are associated with alterations in LV function. Methods and Results—: Myocardial speckle tracking echocardiograms of the RV and LV were obtained before and immediately after a 161-km ultramarathon in 16 healthy adults. Standard echocardiography was used to determine RV size and function and LV eccentricity index. Speckle tracking was used to determine the temporal evaluation of indices of RV and LV function. RV size was significantly increased postrace (RV outflow, 32 to 35 mm, P =0.002; RV inflow, 42 to 45 mm, P =0.027) with an increase in LV eccentricity index (1.03 to 1.13, P =0.006). RV strain (ε) was significantly reduced postrace (−27% to −24%, P =0.004), but there was no change in the rates of ε. Peak ε in all planes of LV motion were reduced postrace (longitudinal, −18.3 to −16.3%, P =0.012; circumferential, −20.2% to −15.7%, P =0.001; radial, 53.4% to 40.3%, P =0.009). Changes in RV size and function correlated with diastolic strain rates in the LV. Conclusions—: This exploratory study demonstrates RV dilatation and reduction in function after an ultramarathon. Further research is warranted to elucidate the mechanisms responsible for these findings. It is not clear what clinical impact might result from consecutive bouts of postexercise RV dysfunction.